Immunological tests can differentiate proliferative from non-proliferative lupus nephritis, but anti-C1q antibodies and urinary erythrocytes have the best predictive power to dist ...

As a novel calcineurin inhibitor with proven efficacy in improving renal outcomes, LUPKYNIS addresses a high unmet medical need. With increasing awareness, supportive guidelines, and potential ...

DelveInsight's "LUPKYNIS Market Size, Forecast, and Market Insight Report" highlights the details around LUPKYNIS, the first ...

Therapy should include either belimumab or a calcineurin inhibitor, plus one or more conventional medications such as ...

LONDON, May 08, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

Two new RCTs of rituximab will soon begin in the United Kingdom: A biomarker-based trial with add-on belimumab and another in ...

Investigators assessed the frequency of lupus flares in patients with kidney failure undergoing dialysis or with a kidney transplant.

Lupus presents unique challenges, particularly for patients with lupus nephritis — a severe form of the condition that affects kidney function and quality of life. Current treatments often come with ...

A global survey conducted by the World Lupus Federation reveals that 47% of people living with lupus report kidney ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

Suzanne and Mohammed, both battling end-stage kidney failure, found hope through a kidney swap at Manipal Hospital. Their ...